Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B E Dunning

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
The American Journal of Physiology|July 11, 1992
Corelease of galanin and NE from pancreatic sympathetic nerves during severe hypoglycemia in dogsP J Havel, T O Mundinger, R C Veith, et al.
The American Journal of Physiology|July 11, 1986
Galanin: a novel pancreatic neuropeptideB E Dunning, B Ahren, R C Veith, et al.
FEBS Letters|June 3, 1991
Human galanin: primary structure and identification of two molecular formsM Bersani, A H Johnsen, P Højrup, et al.
Regulatory Peptides|August 29, 1997
Evidence that vasoactive intestinal polypeptide is a parasympathetic neurotransmitter in the endocrine pancreas in dogsP J Havel, B E Dunning, C B Verchere, et al.
Diabetologia|July 4, 2006
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetesN Matikainen, S Mänttäri, A Schweizer, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 25, 2000
Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinideS Hu, S Wang, B Fanelli, et al.
Diabetes, Obesity & Metabolism|March 22, 2008
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemiaW A Scherbaum, A Schweizer, A Mari, et al.
Diabetes Care|May 26, 2001
Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetesP A Hollander, S L Schwartz, M R Gatlin, et al.
Annals of the New York Academy of Sciences|November 5, 1997
Pharmacological strategies for reduction of lipid availabilityJ E Foley, R C Anderson, P A Bell, et al.
The Journal of Clinical Endocrinology and Metabolism|May 12, 2005
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetesA Mari, W M Sallas, Y L He, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
The American Journal of Physiology|July 11, 1992
Corelease of galanin and NE from pancreatic sympathetic nerves during severe hypoglycemia in dogsP J Havel, T O Mundinger, R C Veith, et al.
The American Journal of Physiology|July 11, 1986
Galanin: a novel pancreatic neuropeptideB E Dunning, B Ahren, R C Veith, et al.
FEBS Letters|June 3, 1991
Human galanin: primary structure and identification of two molecular formsM Bersani, A H Johnsen, P Højrup, et al.
Regulatory Peptides|August 29, 1997
Evidence that vasoactive intestinal polypeptide is a parasympathetic neurotransmitter in the endocrine pancreas in dogsP J Havel, B E Dunning, C B Verchere, et al.
Diabetologia|July 4, 2006
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetesN Matikainen, S Mänttäri, A Schweizer, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 25, 2000
Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinideS Hu, S Wang, B Fanelli, et al.
Diabetes, Obesity & Metabolism|March 22, 2008
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemiaW A Scherbaum, A Schweizer, A Mari, et al.
Diabetes Care|May 26, 2001
Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetesP A Hollander, S L Schwartz, M R Gatlin, et al.
Annals of the New York Academy of Sciences|November 5, 1997
Pharmacological strategies for reduction of lipid availabilityJ E Foley, R C Anderson, P A Bell, et al.
The Journal of Clinical Endocrinology and Metabolism|May 12, 2005
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetesA Mari, W M Sallas, Y L He, et al.
Pageof 6